SERVICES

Discovery & Nonclinical

Plan your next nonclinical study or partner with us for an IND-/CTA-enabling package to get you from research to clinical trials faster.

Contact Us

Nonclinical facilities and locations

Enjoy global support and capacity for your nonclinical and preclinical studies with labs strategically positioned around the world. 
 

TESTIMONIAL

“Labcorp Drug Development is a dependable and reliable source for complicated studies with dedicated and extremely competent study direction.”

–Project leader from a global pharmaceutical company

MARKETPLACE

Your partnering journey starts here

Start strategic conversations that kick-start partnering with the help of MarketPlace by Labcorp. One connection is made every month in our complimentary innovative platform that connects Asset Providers and Asset Seekers. Learn how MarketPlace can propel your path forward.

Early Development Investments

Making your breakthroughs possible with investments that matter 

See how Labcorp is investing worldwide in nonclinical development and how these innovations all started by listening to you and appreciating your changing requirements.

DISEASE MODELS

Oncology models and cell lines

Advance your preclinical oncology compounds with a comprehensive suite of preclinical oncology studies, including in vitro and in vivo pharmacology efficacy models, in vivo imaging technologies as well as focal radiation capabilities.

ADMINISTRATION ROUTE

Inhalation testing capabilities

Inhalation toxicology studies are becoming vital in assessing the safety and potential toxicity of inhaled drugs or chemicals as respiratory diseases including asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF) become more common.

PROGRAMMATIC DEVELOPMENT

IND-/CTA-enabling packages

Accelerate your molecule’s success with early phase development solutions that help to advance your molecule swiftly through critical milestones while maximizing the asset's value. Shave off as much as 30% on your early drug development timeline.

Unleash the Power of Connected Insights

The landscape of development is becoming more complex. You still need your studies delivered on time and on budget. By connecting inspiring science with data, our committed scientific teams uncover insights from preclinical and clinical studies to help you reach your development milestones.

Have Questions?

Educational Insights

Treating Age-Related Macular Degeneration (AMD) With a Novel Stem Cell Therapy

Treating Age-Related Macular Degeneration (AMD) With a Novel Stem Cell Therapy

Blog Posts
The Audacious Goals Initiative (AGI) for regenerative medicine is a program run by the National Eye Institute (NEI), aimed at finding new therapies for eye diseases that remain difficult to treat. Age-related macular degeneration is the leading cause of vision loss in the US, affecting 2.5% of the population, most over the age of 50.
Read More
In Vitro Cytokine Release Assays: Is There Calm After the Storm? | CRA Post I

In Vitro Cytokine Release Assays: Is There Calm After the Storm? | CRA Post I

Blog Posts
Cytokine Release Syndrome (CRS), otherwise known as cytokine storm, is a systemic inflammatory response caused by complications due to disease, infection or an adverse effect of biologic therapy. The clinical symptoms of a cytokine storm are massive release of a potent cocktail of pro-inflammatory cytokines into the general circulatory system, leading to severe multi-organ damage, failure or potentially death. This is an extremely unwanted immunotoxicological side effect in drug development.
Read More

Let's start a conversation

Contact Us